Key Stats for Thermo Fisher Stock
- Current Price: $629.27
- Target Price (Mid): ~$828
- Street Target: ~$631
- Potential Total Return: ~32%
- Annualized Return (Mid): ~6.5% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Thermo Fisher Scientific (TMO) closed at $629.27 on August 21, roughly 45% above the $435 low it touched in May and about 2% under its 52-week high. Buy it a quarter ago and buyers were catching a falling knife the whole sector had given up on. Buy it today, and buyers are paying nearly 34 times trailing earnings for a franchise the market has decided is fixed. The June searches asked whether the pain would end. The question now is the uncomfortable inverse: with a Q2 beat and a raised full-year guide already in the price, what does a buyer at $629 still get paid?
That is not a rhetorical worry. At today’s price, Thermo Fisher trades at about 24 times next-twelve-month earnings and 20.95 times NTM EV/EBITDA, back at the upper end of the band it held before the 2024-to-2025 derating.
The $1 Billion Move Behind the Run
On August 12, Thermo Fisher completed the sale of its microbiology business to European private equity firm Astorg for approximately $1.075 billion, made up of $1.025 billion in cash and a $50 million seller note. The unit generated $645 million in revenue in 2025 inside the slower-growing Specialty Diagnostics segment, and shedding it trims about $200 million from 2026 revenue.
Management repurchased $1 billion of stock in the second quarter, funded by the expected proceeds, before the sale had even closed. CFO Jim Meyer was direct about why on the call: “We elected to use the proceeds for share repurchases and to complete the repurchase ahead of the transaction close based on an assessment of our valuation at that time.” In plain terms, the company sold a low-growth line and recycled the cash into its own shares while they were still depressed. That is the active-management pitch working in real time, and it is the part of the story the earnings recaps skipped.
For anyone scanning the insider-trade headlines, CEO Marc Casper’s early-August stock sales ran through a Rule 10b5-1 plan he adopted on April 27, a pre-scheduled arrangement rather than a discretionary call on the stock.
See historical and forward estimates for Thermo Fisher stock (It’s free!) >>>
Why the Premium Holds, and Where It Strains
The re-rating rests on a clean July quarter (revenue up 10% to $11.99 billion, adjusted EPS up 13% to $6.03, guidance raised), but the more useful question at this price is whether the premium is earned. The durability case is Casper’s: “irrespective of funding environments, if you have really relevant innovation, customers get money,” a claim he backed by pointing to strong high-end instrument adoption even in the still-soft academic market.
Thermo Fisher’s 20.95 times NTM EV/EBITDA sits well above IQVIA at 13.70 times and Charles River at 15.90 times, and above Waters at 19.24 times. The gap is defensible because Thermo Fisher is larger, more diversified, and earns higher returns on capital than a pure clinical-research shop. But it leaves little room for the recovery to stall. The Street’s mean target of roughly $631 sits essentially at the current price, so even a mostly-bullish analyst base now sees limited near-term headroom, and the burden shifts to the fundamentals to justify the multiple rather than the other way around.
See how Thermo Fisher performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $629.27
- Target Price (Mid): ~$828
- Potential Total Return: ~32%
- Annualized Return (Mid): ~6.5% / year
See analysts’ growth forecasts and price targets for Thermo Fisher stock (It’s free!) >>>
TIKR’s mid-case scenario, realized at the end of 2030, lands on a target of around $828. That is roughly 32% of total upside over 4.4 years, or about 6.5% a year. The number answers the chase question honestly: at this entry price, a buyer is signing up for a steady mid-single-digit compounder, not a rebound trade.
Two drivers carry the mid-case revenue CAGR of about 4.6%: the bioproduction business, growing as single-use technologies like DynaDrive get standardized across the industry, and the clinical research franchise, where authorizations have been strong for several quarters and convert to revenue on a roughly six-month lag. On profitability, the margin lever is the PPI Business System, with management guiding to 80 basis points of operating margin expansion this year and the mid-case pushing net margin toward roughly 21%.
The primary risk is the multiple itself. The model already builds in slight compression, and if academic and government spending stalls again or China stays muted at 7.5% of revenue, this year’s re-rating could reverse. The upside is that the biotech recovery broadens and margins expand faster than guided, lifting the annualized return toward the model’s high case. The downside is that a fully valued starting point plus any growth wobble pulls it toward the low case near 3% a year, roughly what cash pays without the equity risk.
Conclusion
The next real test is the Q3 print in late October, and the number to watch is second-half organic growth. Management promised a step-up to 4%. Hit or beat it, with academic and government holding the growth it just found, and the recovery earns the multiple the market has already paid for. Come in at 3% or below, and a stock priced for stabilization has a long way to fall before the model’s mid-single-digit floor looks generous. For a buyer at $629, the easy money is behind the stock. What is left is the bet that this franchise keeps compounding through the next cycle, the way it has through the last three.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Thermo Fisher?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Thermo Fisher, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thermo Fisher alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Thermo Fisher on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
